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noninvasive imaging of vascular 
permeability to predict the risk 
of rupture in abdominal aortic 
aneurysms using an albumin-
binding probe
Lisa c. Adams  1*, Julia Brangsch1,2, carolin Reimann1,2, Jan o. Kaufmann1, 
Kristin nowak1, Rebecca Buchholz3, Uwe Karst  3, Rene M. Botnar  4,5, Bernd Hamm1 & 
Marcus R. Makowski1,4,5
Abdominal aortic aneurysm (AAA) remains a fatal disease. its development encompasses a complex 
interplay between hemodynamic stimuli on and changes in the arterial wall. currently available 
biomarkers fail to predict the risk of AAA rupture independent of aneurysm size. therefore, novel 
biomarkers for AAA characterization are needed. in this study, we used a mouse model of AAA to 
investigate the potential of magnetic resonance imaging (MRi) with an albumin-binding probe to 
assess changes in vascular permeability at different stages of aneurysm growth. Two imaging studies 
were performed: a longitudinal study with follow-up and death as endpoint to predict rupture risk 
and a week-by-week study to characterize AAA development. AAAs, which eventually ruptured, 
demonstrated a significantly higher in vivo MR signal enhancement from the albumin-binding probe 
(p = 0.047) and a smaller nonenhancing thrombus area compared to intact AAAs (p = 0.001). The ratio 
of albumin-binding-probe enhancement of the aneurysm wall to size of nonenhancing-thrombus-area 
predicted AAA rupture with high sensitivity/specificity (100%/86%). More advanced aneurysms with 
higher vascular permeability demonstrated an increased uptake of the albumin-binding-probe. these 
results indicate that MRi with an albumin-binding probe may enable noninvasive assessment of vascular 
permeability in murine AAAs and prediction of rupture risk.
Abdominal aortic aneurysm (AAA) poses an increasing burden on healthcare systems and is among the 
challenges currently facing society, with prevalence ranging from 5% to 10% in Western populations1. AAA 
development is a multifactorial, mainly degenerative process encompassing a complex interplay between hemo-
dynamic stimuli on and changes in the arterial wall, including endothelial dysfunction2–7. Rupture of AAA is a 
life-threatening complication and surgical emergency with high mortality1. While larger (≥55 mm), sympto-
matic, or fast-growing (>10 mm/year) AAAs are recommended to undergo endovascular or operative repair 
as the only available treatment options, patients with smaller AAAs, who are considered to have a lower risk of 
rupture, are often monitored with non-invasive imaging8. By contrast, the management of medium-sized AAAs 
remains controversial9. Apart from diameter and growth rate, there is currently no recognized biomarker for 
evaluating AAA characteristics and rupture risk1. The main limitation of aneurysm diameter as the primary 
criterion for intervention is that it fails to account for smaller aneurysms with high rupture risk and also for large 
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unruptured AAAs10. This is further complicated by the scarcity of longitudinal data on ruptured AAAs, as most 
patients are followed up until meeting criteria for intervention, while prior AAA existence is often unknown in 
patients presenting with rupture.
Therefore, novel biomarkers for the characterization of AAA development and identification of individuals 
at risk for rupture are needed11. Noninvasive magnetic resonance imaging (MRI) with its high spatial resolution 
for evaluation of the aortic wall and aneurysm components is a promising tool in this context12. When com-
bined with target-binding probes, MRI can additionally detect and characterize pathological processes in vivo. 
Gadofosveset trisodium is a clinically approved gadolinium-containing MRI probe that reversibly binds to albu-
min in the arterial and venous system. In case of increased vascular permeability, it may enter the vessel wall and 
interstitium through leaky neovessels or damaged endothelium, as previously demonstrated in an animal model 
of atherosclerosis13,14.
Based on a mouse model of AAA, this study investigates, firstly, if in vivo MRI with gadofosveset could allow 
assessment of vascular permeability at different stages of AAA and, secondly, if it might allow prediction of AAA 
rupture.
Results
Refer to Fig. 1 for details of the study design. Mice were 12 ± 2 weeks old and drug-aïve with a weight between 
27 g and 32 g (see Table 1). Sham-treated mice with a continuous saline infusion for 4 weeks served as controls 
and did not show any signs of AAA development (see Fig. 2).
Longitudinal study for prediction of AAA rupture. To evaluate the potential of delayed-enhancement 
MRI using gadofosveset as a prognostic tool for aneurysm rupture, we performed a longitudinal study of ApoE−/− 
mice with gadofosveset imaging after 1 week of AngII infusion and with fatal aneurysm rupture as the endpoint 
(study 1, n = 18). After one week, we observed that, while there was no significant difference in aneurysm size 
(p = 0.061), increased enhancement (CNR) of the aneurysm wall in combination with the absence of nonenhanc-
ing intraluminal thrombus was associated with an increased rupture risk (see Fig. 3). Thus, the risk of rupture 
could be predicted most accurately by assessing gadofosveset enhancement (CNR) in conjunction with the area 
of nonenhancing organized thrombus (p = 0.009). While surviving animals showed CNR values of 9.74 ± 1.94 
and a nonenhancing thrombus area of 2.77 mm2 ± 1.07 mm2, animals with rupturing aneurysms had CNR values 
Figure 1. Experimental setup. (A) For study 1 (longitudinal), a single MRI session was performed after one 
week (n = 18) with injection of a clinical dose of the albumin-binding probe gadofosveset. After imaging, 
animals were followed up for up to four weeks with death by aneurysm rupture as endpoint. The aim was 
to evaluate the potential of gadofosveset to predict aneurysm rupture. (B) In study 2 (week-by-week study), 
imaging after administration of gadofosveset (0.03 mmol/kg) was performed after 1, 2, 3, and 4 weeks (n = 9 
per group) of angiotensin II infusion. Ex vivo analysis (histology, fluorescence immunohistochemistry, ICP-MS 
and LA-ICP-MS) was performed after the final scan of each week (n = 9 per week) to correlate in vivo with ex 
vivo results. As control, nine sham-treated ApoE−/− mice were implanted with osmotic minipumps primed with 
sodium chloride.
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of 12.25 ± 2.74 and a nonenhancing thrombus area of 0.80 mm2 ± 0.51 mm2 (difference in CNR: p = 0.047, dif-
ference in nonenhancing thrombus area: p = 0.001). The ratio of CNR to the size of the nonenhancing thrombus 
area predicted fatal AAA rupture with 100% sensitivity and 86% specificity (see Fig. 3G).
Abdominal aortic aneurysm progression and gadofosveset uptake. In the week-by-week 
study, ApoE−/− mice with AAAs showed an average increase of 154% ± 12% in aortic diameter after 1 week, 
of 168% ± 15% after 2 weeks, and of 243% ± 19% after 4 weeks (Supplemental Fig. 1). After implantation of 
osmotic minipumps, approximately 25% of ApoE−/− mice died before imaging but none of the sham-treated 
ApoE−/− mice.
On postcontrast, delayed-enhancement MRI, greater enhancement was observed in ApoE−/− mice with AAAs 
compared to sham-treated mice not developing AAA. CNR values were higher for ApoE−/− mice with 4 weeks 
of AngII infusion compared to mice with 2 weeks of AngII infusion (Fig. 4). There was an increase in the CNR of 
the aneurysm region with progression of AAAs in ApoE−/− mice (see Fig. 5A). Histology confirmed in vivo find-
ings, revealing dilatation of the aortic lumen and formation of intraluminal thrombus (see Fig. 4 A4-7 and B4-7). 
Remodelling of the rupture site and adjacent aneurysmal wall was most pronounced in late-stage aneurysms 
(after 4 weeks of AngII infusion). By contrast, signal enhancement was decreased in aneurysm-free sham-treated 
ApoE−/− mice. There was a significant correlation between CNR in the aneurysmal area and gadolinium concen-
tration, as determined by ICP-MS (Fig. 5B).
Albumin measurement. Only minor immunopositive fluorescent areas of albumin were found in the 
aorta of sham-treated ApoE−/− mice, especially in the adventitia. By contrast, in AngII-infused ApoE−/− mice, 
large immunopositive fluorescent areas were observed in the aneurysm wall with higher intensity and larger 
fluorescent areas (Fig. 5C). The correlation of fluorescent-albumin-containing areas with contrast-to-noise ratios 
(p < 0.001) is illustrated in Fig. 5D. Albumin areas were significantly larger after 2 and 4 weeks (24% ± 4% and 
49% ± 7%, respectively) compared with sham-treated ApoE−/− mice (9% ± 5%, p < 0.001).
Gadolinium concentration as determined by inductively coupled mass spectrometry. Absolute 
gadolinium concentrations in AAAs were measured by ICP-MS in 18 mice (n = 3 per time point (week-by-week 
study) and n = 3 sham-treated animals). There was a strong correlation of in vivo CNRs with gadolinium concen-
trations measured ex vivo as a surrogate for aneurysmal albumin (Fig. 5B).
Spatial localization with laser ablation inductively coupled plasma mass spectrome-
try. LA-ICP-MS was used for direct visualization of spatial gadofosveset-associated gadolinium distribution 
in histological samples. AAA sections of ApoE−/− mice with 1, 2, and 4 weeks of AngII infusion and with 4 weeks 
of AngII infusion showed strong co-localization of targeted gadolinium with immunopositive fluorescent areas 
of albumin (Fig. 5). Consistent with the findings for immunofluorescence albumin staining, an increase in gad-
olinium concentration was observed in ApoE−/− mice with 4 weeks of AngII infusion versus 1 week of AngII 
infusion. Similarly, there was an increase of Evans Blue Dye in the aortic tissue of ApoE−/− mice with 4 weeks of 
angiotensin II infusion compared to control animals (also refer to Supplemental Fig. 2A). We could demonstrate, 
that the uptake of gadofosveset correlated with the amount of Evans Blue dye in the aortic tissue (Supplemental 
Fig. 2B). Therefore, our results suggest that AAA are associated with vascular permeability and subsequent extra-
luminal albumin accumulation. This may be used as a biomarker for assessing the rupture risk in murine AAA.
Discussion
In this study, we report a novel approach for the assessment of vascular permeability and the prediction of aneu-
rysm rupture in a murine model of AAA, using an albumin-binding MR probe. AAAs, which ruptured during 
this study, had significantly higher in vivo MR signal enhancement from the albumin-binding probe compared 
to unruptured AAAs. We calculated a ratio of albumin-binding probe enhancement (CNR) of the aneurysm wall 
to the size of nonenhancing thrombus area, which allowed us to predict AAA rupture with high sensitivity and 
specificity.
Previous ex vivo studies demonstrated more marked vascular permeability in patients with AAAs and found 
an association with a higher rupture risk4,5.
Following intravenous administration, gadofosveset binds to albumin in the vascular system, resulting in a 
5- to 10-fold increase in T1 relaxivity compared to standard gadolinium-based contrast agents. If the endothelial 
barrier between blood and the extravascular space is not intact, e.g., as a result of the loss of endothelial cells, 
albumin-bound gadofosveset leaks into the extravascular aneurysm wall. This process can be visualized with high 
spatial resolution using molecular MRI techniques.
Group Age (weeks) Weight (g)
Sham-treated 12 ± 2 28 ± 1
1 week 12 ± 2 29 ± 3
2 weeks 12 ± 2 27 ± 2
3 weeks 12 ± 2 30 ± 1
4 weeks 12 ± 1 29 ± 3
Longitudinal 12 ± 1 27 ± 2
Table 1. Baseline animal characteristics in each group.
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Figure 2. In vivo MRI with an albumin-binding probe and ex vivo assessment in sham animals. (A1) 3D visualization 
showing the suprarenal abdominal aorta (AA) with the renal arteries (rA) of a male ApoE−/− mouse after 4 weeks 
of saline infusion. The green line indicates the orientation of subsequently acquired transverse MRI sequences and 
the corresponding histological sections. (A2) Time-of-flight angiography of the AA. (A3) Delayed-enhancement 
imaging after administration of the albumin-binding probe gadofosveset. Fusion A2/A3 shows a fusion of images 
A2 and A3 for better visualization of in vivo results. A4-A7 are images of ex vivo histology. A4 and its corresponding 
magnification A5 show an albumin-specific staining with only minor immunopositive fluorescent areas of albumin. 
A6 corresponds to a Hematoxylin and Eosin (H&E) staining of the aortic tissue and A7 shows an Elastica van Gieson 
(EvG) staining of elastic fibers. In summary, we see, that no pathological changes of the aortic wall can be observed 
in vivo based on delayed-enhancement imaging with the albumin-binding probe gadofosveset (A3, A2/A3) or 
on corresponding ex vivo histology (A4-7). Abbreviations: H&E: Hematoxylin and Eosin staining; EvG: Elastica 
van Gieson staining of elastic fibers; TOF-MRA: time-of-flight magnetic resonance angiography; AA: suprarenal 
abdominal aorta; RA: right renal artery; gadofosveset: albumin-binding probe. +: vascular lumen in arterial TOF.
5Scientific RepoRtS |         (2020) 10:3231  | https://doi.org/10.1038/s41598-020-59842-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
AAAs are often associated with intraluminal thrombus (ILT)15. The impact of ILT on AAA rupture is still 
controversial and therefore currently unclear, with partly contradictory study results16. While a mechanical 
view considers the intraluminal thrombus as a protective layer, reducing mechanical stress in the aortic wall 
Figure 3. Assessment of aneurysm rupture in animals with stable aortic aneurysm and in animals with fatal 
aortic rupture (longitudinal study). (A,B) Cross-sectional time-of-flight (TOF) angiographies (on the left), 
delayed-enhancement sequences after administration of the albumin-binding probe gadofosveset (centre) and 
delayed-enhanced images fused with magnetic resonance TOF angiography (right). These images show the 
suprarenal abdominal aorta of an ApoE−/− mouse with AAA rupture (A) compared to a surviving ApoE−/− 
mouse. (B) In the fusion images on the right, blue signal indicates little enhancement, whereas red signal 
indicates increased enhancement following administration of an albumin-binding probe. We see, that ApoE−/− 
mice with AAA rupture show significantly increased signal enhancement, as measured by contrast-to-noise 
ratio (p = 0.047, see (C) and a smaller nonenhancing thrombus area (p = 0.001, see (D)). (E-G) show ROC 
curves for contrast-to-noise ratio, size of nonenhancing thrombus and a combination of both. (E) We see, that 
use of the signal from the albumin-binding probe (contrast-to-noise ratio) predicted AAA rupture risk with 
80% sensitivity and 70% specificity. (F) Size of the nonenhancing thrombus area predicted AAA rupture with 
100% sensitivity and 78% specificity. (G) The combined used of both parameters had the highest accuracy for 
predicting aneurysm rupture with 100% sensitivity and 86% specificity compared with each parameter alone. 
Abbreviations: Gadofosveset: albumin-binding probe. *Nonenhancing intraluminal thrombus area; ROC: 
Receiver operating characteristic; TOF-MRA: time-of-flight magnetic resonance angiography; +: vascular 
lumen in arterial TOF.
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Figure 4. In vivo molecular MRI with an albumin-binding probe during the development of aortic aneurysms 
(week-by-week study). (A1) 3D visualizations showing the suprarenal abdominal aorta (AA) with the renal 
arteries (rA) of a male ApoE−/− mouse after 2 weeks of Angiotensin II infusion. The green line indicates the 
orientation of subsequently acquired transverse MRI sequences and the corresponding histological sections. 
(A2) Time-of-flight angiography of the AA showing the vessel lumen. (A3) Delayed-enhancement imaging 
after administration of the albumin-binding probe gadofosveset shows intermediate signal enhancement after 2 
weeks of AngII infusion, indicated by the red arrows and corresponding to albumin accumulation in the arterial 
wall and the thrombus area. Fusion A2/A3 shows a fusion of images A2 and A3 for better visualization of in vivo 
results. Blue signal indicates lower enhancement, whereas green signal shows intermediate enhancement and 
red signal indicates increased enhancement. A4–A7 are images of ex vivo histology. A4 and its corresponding 
magnification A5 show an albumin-specific staining with confluent immunopositive fluorescent areas of 
albumin, confirming the extraluminal accumulation of albumin. A6 corresponds to a Hematoxylin and Eosin 
(H&E) staining of the aortic tissue and A7 shows an Elastica van Gieson (EvG) staining of elastic fibers. In 
summary, we see, that there is pathological vascular permeability in the abdominal aortic aneurysm after 2 
weeks of Angiotensin II infusion with intermediate signal enhancement from the albumin-binding probe, 
corresponding to confluent extraluminal accumulation of Albumin. (B1) 3D visualizations showing the 
suprarenal abdominal aorta (AA) with the renal arteries (rA) of a male ApoE−/− mouse after 4 weeks of 
Angiotensin II infusion. The green line indicates the orientation of subsequently acquired transverse MRI 
sequences and the corresponding histological sections. (B2) Time-of-flight angiography of the AA showing 
the vessel lumen. (B3) Delayed-enhancement imaging after administration of the albumin-binding probe 
gadofosveset shows a strong signal enhancement after 4 weeks of AngII infusion, indicated by the red arrows 
and corresponding to albumin accumulation in the arterial wall and the thrombus area. Fusion B2/B3 shows a 
fusion of images B2 and B3 for better visualization of in vivo results. Blue signal indicates lower enhancement, 
whereas green signal shows intermediate enhancement and red signal indicates increased enhancement. B4-B7 
are images of ex vivo histology. B4 and its corresponding magnification B5 show an albumin-specific staining 
with large immunopositive fluorescent areas of albumin, confirming an increasing extraluminal accumulation 
of albumin. B6 corresponds to a Hematoxylin and Eosin (H&E) staining of the aortic tissue and B7 shows 
an Elastica van Gieson (EvG) staining of elastic fibers. In summary, we see, that there is a further increase in 
vascular permeability in the abdominal aortic aneurysm after 4 weeks of Angiotensin II infusion with strong 
enhancement from the albumin-binding probe, corresponding to extensive extraluminal accumulation of 
Albumin. Abbreviations: H&E: Hematoxylin and Eosin staining; EvG: Elastica van Gieson staining of elastic 
fibers; TOF-MRA: time-of-flight magnetic resonance angiography; gadofosveset: albumin-binding probe; AA: 
suprarenal abdominal aorta; RA: right renal artery; gadofosveset: albumin-binding probe; +: vascular lumen in 
arterial TOF; *: thrombus area.
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and maintaining its stability17,18, another concept focus on the intraluminal thrombus as a biologically active 
entity. According to this concept, the secreted molecules contribute to an inflammatory response and proteolytic 
injury of the arterial wall, culminating in aortic thinning and expansion19. The concept of these two approaches 
might be extended by assuming the presence of intraluminal thrombi with different properties. Zhu et al. found 
brighter, presumably fresher and less organized degraded thrombus to be associated with more rapid aneurysm 
growth, agreeing with another previous study12,20. The results of our study might also be put into this context. 
It can be assumed that predominantly nonenhancing thrombi without or with only minor accumulation of the 
albumin-binding blood pool contrast agent gadofosveset are already older and more organized and thus possibly 
more stable. This could thus serve as an explanation for the reduced rupture risk associated with nonenhancing 
thrombi, which we observed in our study. Still, given the ongoing controversy surrounding the effect of intra-
luminal thrombus on aneurysm stability and rupture, the small sample size and the preclinical setting, it might 
still be premature to evaluate the prognostic value of nonenhancing thrombus for predicting aneurysm rupture.
Figure 5. Ex vivo quantification of in vivo MRI results. (A) Contrast-to-noise ratios measured in control 
animals and in ApoE−/− mice after 1, 2, 3 and 4 weeks of Angiotensin II infusion. Postcontrast (gadofosveset) 
contrast-to-noise ratios show increased signal enhancement with progression of abdominal aortic aneurysm 
(AAA) in ApoE−/− mice. (B) Shows a significant positive correlation between gadofosveset-enhanced contrast-
to-noise ratios and gadofosveset-based gadolinium concentrations as determined by inductively coupled plasma 
mass spectrometry (ICP-MS) (Pearson’s correlation coefficient of R2 = 0.68). (C) Demonstrates the unstained 
frozen section (left), the spatial distribution of gadolinium (from the albumin-specific gadolinium-based probe) 
in aortic aneurysms as assessed by LA-ICP-MS (middle) and the co-localization of albumin-positive areas in 
the fluorescence albumin stain with gadolinium distribution (left). (D) Ex vivo relative fluorescence albumin-
stained areas also demontrate significant correlation with in vivo measured contrast-to-noise ratios (R2 = 0.62). 
(E) Compared to sham-treated animals, Angiotensin II-infused ApoE−/− mice at 4 weeks show significantly 
higher gadolinium content as determined by ICP-MS. n = 9 per group for the MRI experiments. n = 3 per group 
for ICP-MS.
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The relationship between increased signal enhancement of the albumin-binding probe and AAA progression 
we observed in our experiments is consistent with the results reported by prior investigators evaluating vascular 
permeability in an animal model of atherosclerosis14. The presence of increased vascular permeability in coronary 
heart disease was previously established in transmission electron microscopy studies, reporting death of endothe-
lial cells, vascular denudation, and widening of tight junctions14.
With its longer intravascular circulation time and higher relaxivity, gadofosveset also allows longer image 
acquisition times with improved spatial resolution. In this context, Klessen et al. reported an improved image qual-
ity for 10 ml of gadofosveset compared to 30 ml of gadopentetate diglumine21. Clinically, delayed-enhancement 
MRI with gadofosveset has already been used to characterize vascular wall structures and vulnerable plaques and 
to quantify and characterize aneurysm sac contents in patients after endovascular repair, providing information 
on the volumes of unorganized thrombus, organized thrombus, and endoleak14,22,23.
A limitation of the present study is that murine and human abdominal aortic aneurysms occur in different 
anatomic sites (suprarenal versus infrarenal), which may reflect regional differences in collagen and elastin com-
position and thus give rise to different mechanical properties24–26. Compared to other animal models, an advan-
tage of the chosen model is the spontaneous development of aneurysms in response to AngII infusion. Given 
the insufficiently elucidated mechanism of biological distribution and chemical speciation of gadolinium-based 
contrast agents27 as well as potential nephrotoxity, the use of a gadolinium-based probe might be considered a 
general drawback of this approach. However, a stable gadopentetate core and phosphodiester linkage to a lipo-
philic albumin-binding group result in a higher thermodynamic stability and kinetic inertness of the probe used 
here compared to gadolinium diethylenetriamine penta-acetic acid (DTPA)28. While interpreting our data, one 
must realize, that conclusions are based on small sample sizes as well as a preclinical animal model. Finally, it 
should be noted that the results of this study may be very specific to the animal model used, whereas there is no 
clinical evidence for the reported results so far.
While MR-based molecular imaging is still mainly performed with preclinical probes, gadofosveset has the 
advantage that it is already approved clinically, facilitating the translation of our findings to patients with AAA. 
Adding to the possibility of clinical translation, gadofosveset was administered at a clinical dose in the present 
study. Besides, imaging in this study was performed in a clinical 3 Tesla MR scanner. As a result, relaxation, 
rotational correlation, and signal properties could also be transferred to human application. For these reasons, 
results from the present study might be easily translated to patients with cardiovascular disease and AAA. Future 
studies could evaluate the impact this in vivo parameter might have on treatment strategies and their outcomes. In 
the foreseeable future, molecular imaging might therefore assist radiologists and clinicians in the individualized 
assessment and treatment of AAA.
The present study shows the feasibility of contrast-enhanced MRI using albumin-specific gadofosveset to 
noninvasively assess endothelial permeability and risk of rupture in murine AAA.
Materials and Methods
Study design. Twelve-week-old homozygous male ApoE−/− (B6.129P2-ApoEtm1Unc/J) mice were obtained 
from our Research Institute of Experimental Medicine. Animal care, housing, and all procedures regard-
ing the animals as well as the experimental protocols were performed according to the guidelines and regula-
tions of the Federation of Laboratory Animal Science Associations and the local Guidelines and Provisions for 
Implementation of the Animal Welfare Act, as approved by the Regional Office for Health and Social Affairs 
Berlin (LAGeSo).
For aneurysm induction, osmotic minipumps (Alzet, Model-2004, Durect Corporation, USA) were implanted 
subcutaneously into mice at 12 weeks of age and set to deliver angiotensin II (AngII) at a rate of 1000 ng/kg/min 
for up to 4 weeks (n = 36)29. Sham-treated mice received saline-filled pumps.
In the longitudinal study (study 1), imaging was performed after 1 week before and 30 min after injection of 
a clinical dose of 0.03 mmol/kg gadofosveset (n = 18). The mice were followed up for 4 weeks with death as end-
point to evaluate the potential of gadofosveset-enhanced MRI to predict aneurysm rupture. In the week-by-week 
study (study 2), ApoE−/− and sham-treated mice were imaged before and after contrast medium administration, 
and tissue was harvested at weeks 1, 2, 3 and 4 after AngII infusion (n = 9 per group). Following the imaging 
session, histology, fluorescence immunohistochemistry, inductively coupled mass spectroscopy (ICP-MS) and 
laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) were performed. The investigators 
performing these tests were blinded to the intervention (ApoE−/− versus sham-treated ApoE−/− animals), and to 
aneurysm age (1–4 weeks). Results were reported in accordance with the ARRIVE guidelines.
In vivo magnetic resonance experiments. Imaging was performed in a clinical 3 T Siemens MRI scan-
ner (Biograph-mMR, Siemens Healthcare Solutions, Germany) using a 4-channel receive-coil array for mouse 
body applications (Mouse Heart Array, P-H04LE-030, Version1, Rapid Biomedical, Germany). After induction 
of anesthesia, mice were imaged in supine position.
After a three-dimensional (3D) gradient echo scout scan, a non-contrast-enhanced two-dimensional 
time-of-flight angiography (2D TOF) was acquired in transverse orientation for visualization of the abdominal 
aorta with the following parameters: field of view (FOV) of 200 × 200 mm, matrix of 960 × 960, resolution of 
0.2 × 0.2 × 0.5 mm, 40 slices, repetition time(TR)/echo time (TE) of 35 ms/4.44 ms, flip angle of 90°, and band-
width of 124 Hz/Px. A maximum intensity projection (MIP) was then automatically generated to obtain an arte-
rial angiogram of the abdominal aorta for planning the subsequent MR angiography and delayed-enhancement 
scans. A 2D inversion time (TI) scout sequence, planned perpendicular to the abdominal aorta, was used 
to determine the optimal TI for blood signal nulling. Acquisition parameters were as follows: for the 2D TI 
sequence - FOV 340 × 340 mm, matrix 576 × 576, spatial resolution 0.6 × 0.6 × 3 mm, TR/TE 44.91 ms/2.09 ms, 
flip angle 35°, bandwidth 579 Hz/Px, TR between subsequent IR pulses 1000 ms; and for the high-resolution 3D 
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IR FLASH sequence - FOV 57 × 57 mm, matrix 384 × 384, spatial resolution = 0.1 × 0.1 × 0.3 mm, 56 slices, TR/
TE = 1019,72/7,02 ms, flip angle 30°, bandwidth 130 Hz/px, TR between subsequent IR pulses = 1000 ms.
To avoid rapid cooling during MRI, the body temperature (37 °C) of the mice was monitored using an 
MR-compatible heating system (Model 1025, SA Instruments Inc, Stony Brook, NY). For venous access, a 
small-diameter tube with an attached 30 G cannula was used, enabling the injection of contrast agents into the tail vein.
Anesthesia and tissue harvesting. Animals were anesthetized by an intraperitoneal injection of a combi-
nation of medetomidine (500 μg/kg), midazolam (5 mg/kg), and fentanyl (50 μg/kg). For the implantation of the 
osmotic minipumps and the longitudinal setup, a reversal agent (atipamezole (2.5 mg/kg), flumazenil (500 μg/kg), 
and naloxon (1200 μg/kg)) was administered30. After anesthesia and euthanasia by cervical dislocation, terminal 
exsanguination was performed by perfusing the left ventricle with physiological saline for 10 min.
evans blue dye. We assessed vascular permeability by quantification of the leakage of Evans Blue Dye into 
the arterial wall. 0.1 mL of 1% Evans Blue Dye (using phosphate-buffered saline) was injected into the tail vein of 
ApoE−/− mice (n = 3) and sham-operated ApoE−/− mice (n = 3). After 60 minutes, the AAA segment was isolated, 
dried, and weighted. The amount of Evans Blue dye was determined by measuring the absorbance of Evans Blue at 
620 nm and calculation against the standard curve of known pure Evans blue dye concentrations.
immunofluorescence analysis. The abdominal aorta was removed and immediately embedded in 
tissue-freezing medium (OCT compound) for cryosectioning. Abdominal aortic tissues were cut at −20 °C into 
10-µm cryosections and immediately mounted on SuperFrost Plus adhesion slides (Thermo Scientific). Nine indi-
vidual animals were analyzed for each time point (1, 2, 3, and 4 weeks) and nine individuals each for the sham-treated 
group. Transverse sections (10 μm thick) were collected from several sites along the abdominal aorta at distances of 
200 μm, covering the imaged region. Two representative sections per animal were selected for analysis.
Immunofluorescence staining was performed using polyclonal primary anti-mouse serum antibodies (Goat 
polyclonal to Mouse Serum Albumin, ab19194, Abcam, Australia, 1:100) incubated with polyclonal second-
ary antibody labelled with AlexaFluor 568 (goat anti-Rabbit IgG, Thermo Fisher Scientific, Germany, 1:500). 
Fluorescence-positive regions were assessed on digital images by computerized planimetry with the use of ImageJ 
(version 1.51, National Institutes of Health). The fluorescence-positive region was segmented and expressed as a 
percentage of the overall adventitial area. It was matched with LA-ICP-MS images.
Histological analysis. Cryosections (10 µm) were also stained with hematoxylin and eosin (H&E) for over-
all visualization of tissue components and with Miller’s EvG for visualization of elastic fibers. Then slices were 
photographed using a light microscope (Observer Z1, Carl Zeiss Microscopy GmbH, Jena, Germany). Digitized 
images of H&E, EvG, and immunofluorescence sections were used for vessel lumen and aneurysm size measure-
ments (ImageJ software, Version 1.51).
Laser ablation inductively coupled plasma mass spectrometry. For elemental bioimaging, 
LA-ICP-MS was performed using an LSX-213-G2+ laser system (CETAC Technologies, USA), equipped with 
a two-volume HelExII cell connected via Tygon tubing to an ICP-MS spectrometer (ICPMS-2030, Shimadzu, 
Japan). Quantification and visualization were performed with an in-house developed software (Robin Schmid, 
WWU Münster, Germany). Histological samples were ablated via line-by-line scan with a spot size of 15 µm, a 
scan speed of 45 µm/s, and 800 mL/min helium as carrier gas. Subsequent analysis was conducted in collision 
gas mode using He as collision gas and 100 ms integration time for the analyzed isotopes 31P, 64Zn, 158Gd, and 
160Gd. For quantification of Gd, matrix-matched gelatin-based standards were used. Nine gelatin standards (10% 
w/w), including a blank, were spiked with different Gd concentrations ranging from 1 to 5.000 µg/g. There was 
good linear correlation for averaged intensities of scanned lines with a regression coefficient R2 = 0.9999 over this 
concentration range. Limit of detection (LOD) and limit of quantification (LOQ), calculated with the 3σ- and 
10σ-criteria, were 8 ng/g and 28 ng/g Gd, respectively.
inductively coupled plasma mass spectrometry. ICP-MS was used to determine gadolinium concen-
trations. Half of the abdominal aorta/the AAA was collected and snap-frozen in liquid nitrogen (n = 3 per group). 
Before ICP-MS, the samples were digested in 300 μL 70% nitric acid at room temperature overnight, followed by 
dilution in 1 mL of deionized water.
Magnetic resonance imaging analysis. All MR images were analyzed with Visage (version 7.1, 
Visage Imaging, San Diego, CA), and all analyses were performed blinded to the intervention (ApoE−/− ver-
sus sham-treated animals) and to aneurysm age (1, 2, 3, or 4 weeks). 2D regions of interest (ROIs) were drawn 
around areas of signal enhancement within the aneurysm borders or the vessel wall in sham-treated animals in 
delayed-enhancement MR images, anatomically co-localized with high-resolution MR angiography images. In 
the delayed-enhancement gadofosveset sequences, signal from blood was suppressed.
Contrast-to-noise-ratio (CNR) was calculated using the following formula with noise being defined as the 
standard deviation in the background ROI placed in air anterior to the aorta.
CNR = (combined vessel wall and aneurysmal aortic tissue signal intensity − blood signal intensity)/standard 
deviation of image noise.
Statistical analysis. All statistical analysis was performed with the statistical software “R” (version3.2.2, R 
Development Core Team, 2015). A priori analysis was performed to determine required group sizes. An effect 
strength of 0.5 (Cohen’s d) was applied to the main size, with 50% expected/to be detected difference between test 
and sham-treated group.
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Grouped continuous variables were tested for normal distribution with the Shapiro-Wilk test. Continuous 
variables with normal distribution were compared with Student’s t-test. Continuous variables satisfying the 
assumptions of normal distribution were examined by one-way analysis of variance (ANOVA). Variables not 
satisfying the assumption of normality were compared by the Mann-Whitney U-test (two variables). Bar charts 
with standard deviations were generated for visual illustration of CNR values. To assess the risk of rupture in the 
longitudinal study, a receiver operating curve (ROC) analysis was performed to determine the optimal ratio of 
the size of the nonenhancing thrombus area to the CNR for prediction of AAA rupture. Based on this, accuracy 
and sensitivity and specificity were calculated. Univariate calculations were performed using Pearson’s correlation 
coefficient.
Data availability
All data are available in the manuscript and the supplementary material.
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